Review evaluates dosimetric methods and outcomes in metastatic liver disease, highlighting potential improvements.
Yttrium-90 radiation segmentectomy (RS) is well established for hepatocellular carcinoma, but less defined for hepatic metastases. This review evaluates current evidence on dosimetric approaches, clinical outcomes of RS for metastatic disease, and tumor–absorbed dose thresholds for radioembolization in metastatic liver disease.
No takes yet. Share an insight, caveat, or question.
Naser-Tavakolian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: